S&P Futures
4,077.25 -7.50 (-0.18%) Dow Futures
32,565.00 -16.00 (-0.05%) Nasdaq Futures
12,510.50 -49.75 (-0.40%) Russell 2000 Futures
1,831.10 -6.10 (-0.33%) Crude Oil
113.87 +1.47 (+1.31%) Gold
1,817.80 -1.10 (-0.06%)
Gilead Sciences, Inc. (GILD)
Pre-Market:
Chart Events
Performance Outlook
| Previous Close | 62.24 |
| Open | 62.42 |
| Bid | 0.00 x 900 |
| Ask | 0.00 x 800 |
| Day's Range | 61.80 - 63.21 |
| 52 Week Range | 57.19 - 74.12 |
| Volume | |
| Avg. Volume | 9,910,063 |
| Market Cap | 79.247B |
| Beta (5Y Monthly) | 0.42 |
| PE Ratio (TTM) | 17.65 |
| EPS (TTM) | 3.58 |
| Earnings Date | Jul 27, 2022 - Aug 01, 2022 |
| Forward Dividend & Yield | 2.92 (4.62%) |
| Ex-Dividend Date | Jun 14, 2022 |
| 1y Target Est | 69.35 |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for GILD
Related Research
- Gilead Sciences, Inc.Analyst Report: Gilead Sciences, Inc.Gilead Sciences is a California-based biopharmaceutical company that researches, develops, and sells therapies for treating HIV, hepatitis B, hepatitis C, and certain cancers. In October 2020, Gilead's Veklury (remdesivir) became the first approved treatment for COVID-19 in the U.S. Founded in 1987, the company is located in Foster City, California. It has operations in more than 35 countries and approximately 14,400 employees.RatingFair ValueEconomic Moat8 days agoArgus Research
- Business Wire
Gilead and Kite Oncology to Highlight Advances Supporting New Innovations in Cancer Care at the ASCO Annual Meeting
FOSTER CITY, Calif. & SANTA MONICA, Calif., May 17, 2022--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced that more than 20 abstracts, including two oral presentations and four poster discussions, will be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. These data highlight promising targets across diverse tumor types and blood cancers, including hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER
- Benzinga
Gilead Sciences' Can Resume Injectable Lenacapavir Trial(s) For HIV Infection
The FDA has lifted the clinical hold placed on Gilead Sciences Inc's (NASDAQ: GILD) Investigational New Drug Application to evaluate injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis. The agency has removed the clinical hold after reviewing Gilead's comprehensive plan and corresponding data on the storage and compatibility of lenacapavir injection with an alternative vial made from aluminosilicate glass. Related: FDA Slaps Clinical Hold On Gilead's Injectable Lenacapavir
- Zacks
Gilead (GILD) HIV Studies Removed From FDA's Clinical Hold
Gilead (GILD) studies evaluating injectable lenacapavir for HIV treatment and HIV pre-exposure prophylaxis (PrEP) removed from hold.
